BIIB Biogen Inc

Price (delayed)

$230.81

Market cap

$33.9B

P/E Ratio

22

Dividend/share

N/A

EPS

$10.49

Enterprise value

$39.98B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
Biogen's debt has decreased by 2.7% YoY
Biogen's net income has shrunk by 70% YoY and by 19% QoQ
The EPS has plunged by 65% YoY and by 18% from the previous quarter

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
146.89M
Market cap
$33.9B
Enterprise value
$39.98B
Valuations
Price to earnings (P/E)
22
Price to book (P/B)
3.3
Price to sales (P/S)
3.08
EV/EBIT
34.22
EV/EBITDA
16.31
EV/Sales
3.6
Earnings
Revenue
$11.1B
EBIT
$1.17B
EBITDA
$2.45B
Free cash flow
$2.13B
Per share
EPS
$10.49
Free cash flow per share
$14.36
Book value per share
$69.98
Revenue per share
$75
TBVPS
$106.48
Balance sheet
Total assets
$23.81B
Total liabilities
$12.93B
Debt
$7.62B
Equity
$10.43B
Working capital
$2.95B
Liquidity
Debt to equity
0.73
Current ratio
1.7
Quick ratio
1.21
Net debt/EBITDA
2.48
Margins
EBITDA margin
22.1%
Gross margin
82.5%
Net margin
13.9%
Operating margin
17.3%
Efficiency
Return on assets
6.4%
Return on equity
14.5%
Return on invested capital
6.4%
Return on capital employed
6%
Return on sales
10.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-1.28%
1 week
2.43%
1 month
-2.79%
1 year
-15.71%
YTD
-3.8%
QTD
-3.8%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$11.1B
Gross profit
$9.16B
Operating income
$1.92B
Net income
$1.55B
Gross margin
82.5%
Net margin
13.9%
BIIB's operating income has dropped by 71% year-on-year and by 13% since the previous quarter
Biogen's net income has shrunk by 70% YoY and by 19% QoQ
Biogen's operating margin has plunged by 63% YoY and by 8% from the previous quarter
Biogen's net margin has plunged by 61% YoY and by 15% from the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
22
P/B
3.3
P/S
3.08
EV/EBIT
34.22
EV/EBITDA
16.31
EV/Sales
3.6
The EPS has plunged by 65% YoY and by 18% from the previous quarter
The P/E is 39% above the 5-year quarterly average of 15.8 and 12% above the last 4 quarters average of 19.6
BIIB's price to book (P/B) is 23% lower than its 5-year quarterly average of 4.3 and 20% lower than its last 4 quarters average of 4.1
The equity has contracted by 3.1% YoY and by 3% from the previous quarter
The stock's price to sales (P/S) is 25% less than its 5-year quarterly average of 4.1 and 14% less than its last 4 quarters average of 3.6
Biogen's revenue has decreased by 22% YoY and by 5% from the previous quarter

Efficiency

How efficient is Biogen business performance
The ROIC has plunged by 83% YoY and by 35% from the previous quarter
The ROS has plunged by 76% YoY and by 32% from the previous quarter
Biogen's return on assets has shrunk by 67% YoY and by 18% QoQ
The ROE has plunged by 66% YoY and by 19% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 84% more than the total liabilities
The company's quick ratio fell by 25% YoY and by 21% QoQ
The current ratio has contracted by 21% from the previous quarter and by 17% YoY
Biogen's debt is 27% less than its equity
Biogen's debt has decreased by 2.7% YoY
The equity has contracted by 3.1% YoY and by 3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.